Pure Global
NCT05965856

A Study of BL-B01D1+SI-B003 in the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 Combined With SI-B003 in the Treatment of Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Urothelial Carcinoma
Drug/Device/Intervention
BL-B01D1
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
Aug 01, 2023
End date
Aug 01, 2025
Enrollment
40 participants
Primary outcome

Objective response rate (ORR),Recommended Phase II Dose (RP2D)

Summary

Objective: To investigate the efficacy, safety and tolerability of BL-B01D1+SI-B003
 combination in patients with locally advanced or metastatic urothelial carcinoma and other
 solid tumors, and to further explore the optimal dose and mode of combination.

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05965856
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05965856 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sichuan Baili Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.